LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Treatment of advanced prostate cancer with a combination of luteinising hormone-releasing hormone analogues and anti-androgens is advisable for the initial 2 weeks, in patients with newly diagnosed, extensive disease. Advances in long-term combination treatment are questionable until results of phase III studies become available. Reference is made to poster presentations at the International Symposium on Endocrine Therapy.
Denis
L
L
A-Z Middelheim, Antwerpen, Belgium.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D017273:Goserelin; D005485:Flutamide; D002064:Buserelin